The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Aurigene Pharmaceutical Services, the CRDMO arm of India-based Dr. Reddy’s, has signed a non-binding Memorandum of Understanding (MoU) with Kainomyx, a US-based company with a proprietary platform that helps target cytoskeletal proteins of parasites, for the development and commercialization of an affordable anti-malarial drug in in the US, Europe, and in low and middle-income countries.
Aurigene Pharmaceutical Services Limited (Aurigene), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 6500 m2 (70,000 sq ft) in Hyderabad, India.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
